KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Amortization of Deferred Charges (2016 - 2018)

Halozyme Therapeutics (HALO) has disclosed Amortization of Deferred Charges for 7 consecutive years, with -$455000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Amortization of Deferred Charges rose 26.26% to -$455000.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $1.5 million, a 12.27% decrease, with the full-year FY2018 number at $1.5 million, down 12.27% from a year prior.
  • Amortization of Deferred Charges was -$455000.0 for Q4 2018 at Halozyme Therapeutics, down from $303000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $3.6 million in Q2 2016 to a low of -$3.0 million in Q3 2016.
  • A 5-year average of $526111.1 and a median of $442000.0 in 2014 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: soared 147.11% in 2014, then tumbled 442.82% in 2016.
  • Halozyme Therapeutics' Amortization of Deferred Charges stood at $415000.0 in 2014, then decreased by 13.73% to $358000.0 in 2015, then increased by 26.26% to $452000.0 in 2016, then plummeted by 236.5% to -$617000.0 in 2017, then increased by 26.26% to -$455000.0 in 2018.
  • Per Business Quant, the three most recent readings for HALO's Amortization of Deferred Charges are -$455000.0 (Q4 2018), $303000.0 (Q3 2018), and $345000.0 (Q2 2018).